Trevi Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$14.04

+0.39%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:29 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $13.99
Volume: 4,476
Day's high: —
Day's low: —

In brief

Trevi Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $2.00B.
Its shares closed at $13.99 on 4 Nov 2026, up 28.8% over the past year.
From India you can buy TRVI in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Trevi Therapeutics, Inc. (TRVI) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole TRVI share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade TRVI options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +6.1% (SPY −1.6%, XLV +13.5%). 3 months: −25.0% (SPY −0.4%, XLV +15.5%). 1 year: +28.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: TRVI, SPY and XLV · as of 4 Nov 2026
Short interest at 11.2% of shares outstanding
16.0M shares were sold short at the 15 Oct 2026 settlement, 11.2% of the 142.5M shares outstanding; covering them would take 4.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $13.99 was 3.2% below its 50-day average ($14.44) and 2.8% below its 200-day average ($14.39). It has closed below the 200-day for 25 sessions, since 1 Oct 2026. The 50-day average crossed above the 200-day on 14 Mar 2024, 663 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
40% of the way up its 52-week range
Closed at $13.99 on 4 Nov 2026: 30.8% below the 52-week high of $20.22 (17 Jul 2026) and 42.4% above the low of $9.82 (19 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+6.1%

6 months−1.9%

1 year+28.8%

5 years+1046.3%

Newswire

About

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Website

Notable moves

March 10, 2025
+41.16%
December 12, 2024
+44.58%
April 7, 2022
+56.84%

Trevi Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$14.04

+0.39%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:29 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $13.99
Volume: 4,476
Day's high: —
Day's low: —

In brief

Trevi Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $2.00B.
Its shares closed at $13.99 on 4 Nov 2026, up 28.8% over the past year.
From India you can buy TRVI in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Trevi Therapeutics, Inc. (TRVI) shares from India?

Do I need the price of a whole TRVI share to invest?

How much can I invest in US stocks in a year?

Can I trade TRVI options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +6.1% (SPY −1.6%, XLV +13.5%). 3 months: −25.0% (SPY −0.4%, XLV +15.5%). 1 year: +28.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: TRVI, SPY and XLV · as of 4 Nov 2026
Short interest at 11.2% of shares outstanding
16.0M shares were sold short at the 15 Oct 2026 settlement, 11.2% of the 142.5M shares outstanding; covering them would take 4.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $13.99 was 3.2% below its 50-day average ($14.44) and 2.8% below its 200-day average ($14.39). It has closed below the 200-day for 25 sessions, since 1 Oct 2026. The 50-day average crossed above the 200-day on 14 Mar 2024, 663 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
40% of the way up its 52-week range
Closed at $13.99 on 4 Nov 2026: 30.8% below the 52-week high of $20.22 (17 Jul 2026) and 42.4% above the low of $9.82 (19 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+6.1%

6 months−1.9%

1 year+28.8%

5 years+1046.3%

Newswire

About

Website

Notable moves

March 10, 2025
+41.16%
December 12, 2024
+44.58%
April 7, 2022
+56.84%

Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. in brief

Ahead of SPY, behind its sector fund XLV over 1 year

Short interest at 11.2% of shares outstanding

Below its 50- and 200-day averages

40% of the way up its 52-week range

Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. in brief

Ahead of SPY, behind its sector fund XLV over 1 year

Short interest at 11.2% of shares outstanding

Below its 50- and 200-day averages

40% of the way up its 52-week range